实体瘤癌症治疗药物研发商Intensity Therapeutics完成630万美元融资-动脉网

Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025

CISION 等信源发布 2025-08-04 19:47



可切换为仅中文







• Cash runway extended into the second half of 2026

• 现金跑道延长至2026年下半年

• Average sales price per share was over 10% higher than the

• 平均每股销售价格高出10%以上

June 2025

2025年6月

public offering price

公开发行价

SHELTON, Conn.

康涅狄格州谢尔顿

，

Aug. 4, 2025

2025年8月4日

/PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq:

/PRNewswire/ -- Intensity Therapeutics, Inc. (纳斯达克:

INTS

整数集

) ('Intensity' or 'the Company'), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, announces that in .

）（“Intensity”或“公司”），一家处于后期临床阶段的生物技术公司，专注于利用其专有的非共价偶联技术发现和开发新型瘤内癌症疗法，旨在杀死肿瘤并增强免疫系统对癌症的识别能力，宣布在。

July 2025

2025年7月

the Company added

公司补充道

$6.6 million

660万美元

in gross proceeds (

总收入（

$6.3 million

630万美元

net) by selling 19,868,658 shares of its common stock via its At-the-Market offering (the 'ATM') at an average price of

通过其场内发行（ATM）以平均价格出售19,868,658股普通股，净收入为

$0.3323

0.3323美元

per share. Following such sales of common stock pursuant to the ATM, the Company has 46,035,081 shares of common stock issued and outstanding as of

每股。在根据ATM进行普通股出售后，公司截至当日已发行和流通的普通股为46,035,081股。

July 31, 2025

2025年7月31日

。

'We were able to take advantage of strong liquidity and favorable prices in our stock last month. The proceeds from these ATM sales strengthen our balance sheet considerably and allow us to continue to advance the clinical trials into the second half of 2026,' said

“上个月，我们能够利用股票的强劲流动性和有利价格。这些ATM销售的收益大大增强了我们的资产负债表，并使我们能够继续推进临床试验至2026年下半年。”

Lewis H. Bender

刘易斯·H·本德

, President and CEO of Intensity. 'We are also pleased to announce that the average price per share for these ATM sales was more than 10% higher than our recently completed

，Intensity总裁兼首席执行官。“我们还高兴地宣布，这些ATM销售的平均每股价格比我们最近完成的高出10%以上

June 2025

2025年6月

public offering, and the costs to raise this incremental capital were much lower. We will continue to be selective and strategic in the deployment of the remainder of the ATM.'

公开发行，且筹集这笔增量资本的成本要低得多。我们将继续在部署ATM的剩余部分时保持选择性和战略性。

About At the Market Transactions

关于市场交易

'At-the-Market' (ATM) offerings, also known as 'ATM' programs, refer to a method where a public company sells its newly issued shares directly into the existing trading market at the prevailing market price, rather than through a traditional underwritten offering. This approach allows companies to raise capital opportunistically and incrementally, as needed, with minimal disruption to the market and typically lower costs..

“ ATM ”（At-the-Market）发行，也称为“ ATM ”计划，是指上市公司以当前市场价格直接在现有交易市场出售新发行的股票，而不是通过传统的包销方式进行。这种方式使公司能够根据需要灵活地、逐步地筹集资金，同时对市场的干扰最小，并且通常成本较低。

About INT230-6

关于INT230-6

INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform. The drug consists of two proven, potent anti-cancer agents, cisplatin and vinblastine sulfate, and a diffusion and cell penetration enhancer molecule ('SHAO') that facilitates the dispersion of potent cytotoxic drugs throughout tumors, allowing the active agents to diffuse into cancer cells.

INT230-6是Intensity公司的主要专利研究性候选产品，设计用于直接瘤内注射。INT230-6是利用Intensity公司专有的DfuseRx℠技术平台发现的。该药物包含两种已验证的强效抗癌药物——顺铂和硫酸长春碱，以及一种扩散和细胞渗透增强剂分子（“SHAO”），能够促进强效细胞毒性药物在肿瘤内的扩散，并使活性成分渗透进入癌细胞。

These agents remain in the tumor, resulting in a favorable safety profile. In addition to local disease control and direct tumor killing, INT230-6 causes a release of a bolus of neoantigens specific to the malignancy, leading to immune system engagement and systemic anti-tumor effects. Importantly, these effects are mediated without immunosuppression, which often occurs with systemic chemotherapy..

这些药物仍留在肿瘤内，从而形成了良好的安全性。除了局部疾病控制和直接杀伤肿瘤外，INT230-6还能够释放出针对恶性肿瘤的新抗原，引发免疫系统参与并产生全身性抗肿瘤效果。重要的是，这些效果的产生并未伴随免疫抑制，而免疫抑制往往在系统性化疗中出现。

About Intensity Therapeutics

关于强度治疗学

Intensity is a late-stage clinical biotechnology company whose novel engineered chemistry enables aqueous cytotoxic-containing drug formulations to mix and saturate a tumor's dense, high-fat, pressurized environment following direct intratumoral injection. As a result of the saturation, Intensity's clinical trials have demonstrated the ability of INT230-6 to kill tumors and elicit an adaptive immune response within days of injection, representing a new approach to cancer cell death that holds the potential to shift the treatment paradigm and turn many deadly cancers into chronic diseases even for malignancies that do not respond to conventional immunotherapy.

Intensity是一家处于晚期临床阶段的生物技术公司，其新型工程化学技术使得含细胞毒性药物的水性制剂能够在直接瘤内注射后，渗透并饱和肿瘤致密、高脂肪、高压的环境。由于这种饱和效果，Intensity的临床试验表明，INT230-6能够在注射后的数天内杀死肿瘤并引发适应性免疫反应，这代表了一种全新的癌细胞死亡机制，有望改变治疗模式，将许多致命癌症转化为慢性疾病，甚至对那些对传统免疫疗法无反应的恶性肿瘤也同样有效。

Intensity has completed two clinical studies and enrolled over 200 patients using INT230-6: a Phase 1/2 dose escalation study in metastatic cancers including sarcomas .

Intensity已经完成了两项临床研究，并在包括肉瘤在内的转移性癌症的1/2期剂量递增研究中招募了200多名患者使用INT230-6。

(NCT03058289

(NCT03058289)

), and a Phase 2 randomized control clinical trial in locally advanced breast cancer (the 'INVINCIBLE-2 Study') (

），以及在局部晚期乳腺癌中进行的二期随机对照临床试验（“无敌-2研究”）（

NCT04781725

) in women without undergoing chemotherapy prior to their surgery. The Company initiated a Phase 3 trial in soft tissue sarcoma (the 'INVINCIBLE-3 Study') (

在未接受化疗的女性中进行手术前。公司启动了软组织肉瘤的第三阶段试验（“INVINCIBLE-3研究”） (

NCT06263231

), testing INT230-6 as second or third-line monotherapy compared to the standard of care ('SOC') with overall survival as an endpoint. Intensity also initiated a Phase 2 study (the 'INVINCIBLE-4 Study') (

)，测试INT230-6作为二线或三线单药疗法与标准治疗（'SOC'）的比较，以总生存期为终点。Intensity还启动了一项二期研究（“INVINCIBLE-4研究”）（

NCT06358573

) in collaboration with the Swiss Cancer Group, formerly the Swiss Group for Clinical Cancer Research, SAKK, as part of a Phase 2/3 program evaluating INT230-6 followed by the SOC immunochemotherapy and the SOC alone for patients with presurgical triple-negative breast cancer. Pathological complete response ('pCR') is the endpoint.

) 与瑞士癌症组（前身为瑞士临床癌症研究组 SAKK）合作，作为评估 INT230-6 联合标准免疫化疗（SOC）及单独使用 SOC 的 2/3 期项目的一部分，针对术前三阴性乳腺癌患者。病理完全缓解（'pCR'）是终点指标。

For more information about Intensity, including publications, papers, and posters about its novel approach to cancer therapeutics, visit .

有关Intensity的更多信息，包括关于其癌症治疗新方法的出版物、论文和海报，请访问。

www.intensitytherapeutics.com

。

Forward-Looking Statements

前瞻性声明

Certain statements in this press release may constitute 'forward-looking statements' within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the Company's expected future plans, cash runway, development activities, projected milestones, business activities or results.

本新闻稿中的某些陈述可能构成经修订的1995年美国《私人证券诉讼改革法案》意义上的“前瞻性陈述”。这些陈述包括但不限于与公司未来计划、现金跑道、开发活动、预计里程碑、业务活动或结果相关的陈述。

When or if used in this communication, the words 'may,' 'could,' 'should,' 'anticipate,' 'believe,' 'estimate,' 'expect,' 'intend,' 'plan,' 'predict' and similar expressions and their variants, as they relate to the Company or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management's current expectations and projections about future events.

在本沟通中，如果使用了“可能”、“能够”、“应该”、“预期”、“相信”、“估计”、“预计”、“打算”、“计划”、“预测”等词语及其变体，与公司或其管理层相关的表述可能构成前瞻性陈述。本新闻稿中包含的前瞻性陈述基于管理层当前的预期和对未来事件的预测。

Nevertheless, actual results or events could differ materially from the plans, intentions, and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: the initiation, timing, progress and results of future preclinical studies and clinical trials and research and development programs; the need to raise additional funding before the Company can expect to generate any revenues from product sales; plans to develop and commercialize product candidates; the timing or likelihood of regulatory filings and approvals; the ability of the Company's research to generate and advance additional product candidates; the risk that product candidates that appear promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials; the implementation of the Company's business model, strategic plans for the Company's busines.

然而，实际结果或事件可能与前瞻性陈述中披露的计划、意图和预期有重大差异。这些风险和不确定性包括许多我们无法控制的因素：未来临床前研究和临床试验以及研发项目的启动、时间、进展和结果；公司在产生任何产品销售收入之前需要筹集额外资金的需求；开发和商业化候选产品的计划；监管文件提交和批准的时间或可能性；公司研究生成并推进更多候选产品的能力；在早期研究和临床试验中表现良好的候选产品未能在更大规模或后期临床试验中证明其安全性和/或有效性的风险；公司商业模式的实施以及公司业务的战略规划。

December 31, 2024

2024年12月31日

and in the Company's subsequent SEC ﬁlings, which can be obtained on the SEC website at

并在公司随后的SEC文件中有所提及，这些文件可以在SEC网站上获取。

www.sec.gov

. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law..

读者应注意不要过分依赖前瞻性声明，这些声明仅在其作出的日期有效，并反映了管理层当前的估计、预测、期望和信念。公司不打算更新任何此类前瞻性声明，并明确表示不承担更新本新闻稿中所含信息的义务，除非法律要求。

Investor Relations Contact:

投资者关系联系人:

Justin Kulik

贾斯汀·库利克

Justin@coreir.com

贾斯汀@coreir.com

CORE IR

核心IR

(516) 222-2560

Media Contact:

媒体联系人: